• Ether Lipids Shape B-Cell Humoral Immunity

  2026-08-19

  This study provides causal evidence that B-cell-intrinsic ether lipid biosynthesis, mediated by the peroxisomal enzyme PexRAP, supports germinal-center development, antibody production, and affinity maturation. By combining inducible Dhrs7b loss-of-function models with imaging mass spectrometry and immunization experiments, the authors connect lipid composition to B-cell survival through control of reactive oxygen species and membrane peroxidation.

• Leucovorin Calcium in Methotrexate Rescue Models

  2026-08-19

  Leucovorin Calcium, also called calcium folinate, supplies a reduced folate rationale for studying methotrexate rescue and the folate metabolism pathway. Its defined aqueous solubility and frozen-storage specification support controlled cell proliferation assays, while gastric cancer assembloid evidence shows why stromal context should be included when evaluating drug response.

• Wnt Agonist 1: A Causal Test for Wnt–GPX4

  2026-08-18

  Wnt agonist 1 (BML-284) provides a controlled way to test how canonical Wnt signaling influences transcription, differentiation, and redox phenotypes. This article develops an assay strategy that connects TCF activity with the Wnt/NR2F2/GPX4 chemoresistance axis while distinguishing established evidence from testable research hypotheses.

• CCG-1423 RhoA Inhibitor Workflow Guide

  2026-08-18

  CCG-1423 is a pathway-level RhoA inhibitor for separating MRTF-A nuclear signaling from actin-dependent cytoskeletal effects. This guide shows how to apply it in cancer research, build mechanistic controls, and cautiously extend the workflow to RhoA/ROCK-dependent barrier and viral-entry models.

• AG-490 for JAK2/STAT6 Macrophage Studies

  2026-08-17

  Use AG-490 as a pharmacological probe to test whether hepatoma-derived exosomes drive macrophage polarization through JAK2-linked signaling. This workflow combines dose-aware pathway inhibition, exosome quality controls, phosphoprotein analysis, and functional validation for more defensible cancer research results.

• AZD3463 Workflow for ALK/IGF1R Inhibition

  2026-08-17

  AZD3463 combines ALK and IGF1R pathway coverage with practical workflows for neuroblastoma signaling, apoptosis, autophagy, and combination studies. This guide connects dose-response design, mutant ALK models, pathway validation, and troubleshooting to reproducible bench execution.

• JSH-23: Reliable NF-κB Assay Design

  2026-08-16

  JSH-23 (SKU B1645) is a small-molecule NF-κB inhibitor for dissecting p65 nuclear localization, inflammatory transcription, and cytokine responses in cell and animal models. This scenario-based guide explains solvent handling, dose selection, controls, interpretation, and vendor evaluation for more defensible inflammation research.

• Clarithromycin CYP3A Assay Workflow

  2026-08-15

  Build more interpretable CYP3A inhibition experiments with Clarithromycin, from solvent handling and concentration-response design to pathway-specific controls. The workflow links statin metabolism interaction and anticoagulant pharmacology questions without confusing CYP3A effects with non-CYP clearance pathways.

• Tamoxifen: SERM Mechanisms and Research Use

  2026-08-14

  Tamoxifen is a selective estrogen receptor modulator used in breast cancer research and CreER-mediated gene knockout workflows. Evidence supports tissue-selective estrogen receptor activity, while mouse data show that high-dose prenatal exposure can cause developmental malformations.

• SB 431542 Workflow for ALK5 Signaling Studies

  2026-08-14

  Use SB 431542 as a pathway-dissection tool to connect ALK5 activity with Smad2 phosphorylation, EMT, proliferation, and invasion. This practical workflow also shows how to distinguish mechanism-focused experiments from broader glioma and anti-tumor immunology applications.

• Gefitinib (ZD1839) EGFR Assay Workflows

  2026-08-13

  Build more informative EGFR perturbation assays with Gefitinib (ZD1839), from phosphorylation kinetics and viability studies to blue-light skin-barrier models. This workflow emphasizes causal controls, calibrated exposure, and practical troubleshooting rather than treating pathway inhibition as a single endpoint.

• Wnt Agonist 1: From Wnt Biology to Chemoresistance

  2026-08-13

  Wnt agonist 1 (BML-284) provides a practical pharmacological input for studying β-catenin–TCF signaling, cellular differentiation, and the Wnt/NR2F2/GPX4 axis implicated in platinum resistance in lung cancer brain metastasis.

• IWR-1-endo Workflow for Wnt Signaling Inhibition

  2026-08-12

  Build reproducible Wnt/β-catenin assays with IWR-1-endo by combining controlled DMSO handling, concentration-response design, and orthogonal pathway readouts. The workflow also shows how single-nucleus study design can sharpen cell-state analysis without confusing atrial fibrillation findings with evidence for Wnt activity.

• Cytochalasin B: Actin Dynamics and Cell Entry

  2026-08-12

  Cytochalasin B, also known as NSC 107658, is a reversible actin-filament perturbant used as a cytoskeletal research tool. In a peer-reviewed Drosophila S2-cell model, actin disruption reduced intracellular Spiroplasma eriocheiris, linking filament integrity to pathogen entry and intracellular infection.

• Quercetin Blocks Ferroptosis in Wilson’s Disease

  2026-08-11

  A 2026 Phytomedicine study identifies ferroptosis and phospholipid remodeling as important components of Wilson’s disease–associated liver injury. Using complementary animal, cellular, lipidomic, and target-validation approaches, the researchers show that Quercetin acts through the ACSL4/LPCAT3/ALOX15 axis to reduce lipid peroxidation, oxidative stress, and mitochondrial dysfunction.

456 records 1/31 page Next 12345 下5页 Last page